Compare Devon Energy Corp (DVN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Recursion Pharmaceuticals Inc — how do they compare? Devon Energy Corp trades at $48.79 (market cap $53.81B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Devon Energy Corp is far larger — about 25.1× Recursion Pharmaceuticals Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DVN | RXRX | |
|---|---|---|
Market Cap | $53.81B | $2.14B |
Volume | 11,556,740 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $52.07 | $6.79 |
52-Week Low | $31.74 | $2.84 |
Typical Hold Time | 136 Days | 22 Days |
Enterprise Value | $64.55B | $1.66B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 10.41 and net margin of 16.67%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent news highlights activist investor pressure for strategic alternatives and potential asset sales, while analyst consensus remains strongly bullish with a $62.40 price target representing 30% upside.
DVN presents a compelling value opportunity with attractive valuation metrics and strong cash flow generation. However, investors face risks from oil price volatility, execution challenges in asset sales, and competitive pressures in the shale sector. The company's Permian Basin focus and potential strategic moves provide catalysts, but macroeconomic headwinds could impact near-term performance.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
